Geode Capital Management LLC Purchases 2,229 Shares of Enovis Co. (NYSE:ENOV)

Geode Capital Management LLC increased its position in Enovis Co. (NYSE:ENOV) by 0.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 923,666 shares of the company’s stock after purchasing an additional 2,229 shares during the quarter. Geode Capital Management LLC owned approximately 1.62% of Enovis worth $40,544,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. UMB Bank n.a. boosted its holdings in Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after purchasing an additional 437 shares during the period. Pinnacle Bancorp Inc. raised its position in shares of Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after buying an additional 300 shares in the last quarter. FMR LLC boosted its stake in shares of Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after buying an additional 484 shares during the period. XTX Topco Ltd acquired a new stake in Enovis during the third quarter worth approximately $217,000. Finally, Legacy Capital Wealth Partners LLC bought a new position in Enovis during the 4th quarter worth $228,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reissued a “buy” rating and set a $64.00 target price on shares of Enovis in a report on Wednesday, April 9th.

Enovis Price Performance

Enovis stock opened at $31.41 on Wednesday. Enovis Co. has a one year low of $29.32 and a one year high of $57.08. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The stock’s 50 day moving average is $38.29 and its 200 day moving average is $42.39. The firm has a market cap of $1.79 billion, a P/E ratio of -14.34 and a beta of 1.86.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. As a group, research analysts expect that Enovis Co. will post 2.79 EPS for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.